首页> 外文期刊>European addiction research >History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders
【24h】

History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders

机译:终身大麻使用的历史与精神分裂症谱系障碍的更好的认知和更糟糕的真实功能有关

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Data on associations between cannabis use and psychopathology, cognition and functional impairment in schizophrenia spectrum disorders (SSD) is controversial. Objectives: To examine the effect of cannabis on psychopathology, cognition and real-world functioning in SSD patients. Method: Naturalistic cross-sectional study, 123 clinically stable SSD outpatients. Assessment: demographic and clinical data, psychometric evaluation: Positive and Negative Syndrome, Hamilton Depression Rating, Clinical Global Impression (CGI), Personal and Social Performance and Screen for Cognitive Impairment in Psychiatry (SCIP) scales. Patients were classified as cannabis user patients (CUP) and non cannabis user patients (NCUP) according to self-report, both lifetime and last year. Statistical analysis: chi-square, Student t test, ANOVA (Duncan post hoc), and general linear model analysis for adjusting for antipsychotic doses. Results: Mean age 40.75, 66.7% male, single (66.7%), prior hospital admissions 2.75, mean length of illness 13.85 years. 53.7% were lifetime cannabis users and 8.9% last year users. Lifetime CUP had more hospitalizations (p = 0.013) at a younger age (p = 0.002), and showed better cognitive functioning globally (CGI-C: p = 0.045) and on working memory and processing speed (SCIP-2: p = 0.039; SCIP-5: p = 0.033) and worse functioning in socially useful activities (p = 0.014) than NCUP. All these differences remained after adjusting for antipsychotic doses. Last year cannabis users had worse mood (Hamilton Depression Rating Scale 9.66 vs. 5.64; p = 0.002), but this difference disappears when adjusting for antipsychotic doses. Conclusions: Lifetime cannabis use is associated with better working memory and processing speed and worse real-world functioning in the area of socially useful activities in patients with schizophrenia-related disorders. Clinicians should, therefore, be aware of it to provide patient-centred care in their daily clinical practice. (C) 2019 S. Karger AG, Basel
机译:背景:在精神分裂症谱系障碍(SSD)中大麻使用和精神病理学,认知和功能损伤的关联数据的数据是有争议的。目标:检查大麻对SSD患者的精神病理学,认知和现实功能的影响。方法:自然主义横截面研究,123临床稳定的SSD门诊患者。评估:人口统计学和临床​​数据,心理测量评估:积极和消极综合征,汉密尔顿抑郁等级,临床全球印象(CGI),个人和社会绩效以及精神病学(SCIP)鳞片的认知障碍筛选。患者被归类为大麻用户患者(杯子)和非大麻用户患者(NCUP)根据自我报告,终身和去年。统计分析:Chi-Square,学生T测试,ANOVA(Duncan Post Hoc),以及用于调整抗精神剂量的一般线性模型分析。结果:平均年龄40.75,66.7%男性,单身(66.7%),先前医院入院2.75,均值的疾病长度为13.85岁。 53.7%是终身大麻用户和去年用户的8.9%。寿命杯在较小的年龄(p = 0.002)上有更多住院治疗(p = 0.013),并在全球(CGI-C:P = 0.045)和工作存储器和处理速度上显示更好的认知功能(SCIP-2:P = 0.039 ; SCIP-5:P = 0.033),在社会有用的活动中运作更差(P = 0.014)比NCUP。调整抗精神剂量后,所有这些差异仍然存在。去年大麻的心情更糟糕(汉密尔顿抑郁率评级为9.66与5.64; P = 0.002),但在调整抗精神剂量时,这种差异消失。结论:寿命大麻使用与精神分裂症相关疾病患者的社会有用的活动领域更好地与更好的工作记忆和处理速度以及更糟糕的现实功能相关。因此,临床医生应该意识到它在日常临床实践中提供以患者为中心的护理。 (c)2019年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号